Skye Bioscience (FRA:09R) Cyclically Adjusted PB Ratio: (As of Jul. 25, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:09R Skye Bioscience Inc FRA:09R
19 GF Score
Price €0.55
! 1 Warning Sign
View Full Analysis

What is Skye Bioscience Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Skye Bioscience  (FRA:09R) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Skye Bioscience Cyclically Adjusted PB Ratio Related Terms


Skye Bioscience Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Skye Bioscience's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Skye Bioscience Cyclically Adjusted PB Ratio Chart

Skye Bioscience Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Skye Bioscience Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:09R vs PLRZ, NEUP, LGVN: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Skye Bioscience's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Skye Bioscience Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Skye Bioscience's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Skye Bioscience's Cyclically Adjusted PB Ratio falls into.


FRA:09R
19GF Score
Skye Bioscience Inc FRA:09R
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Skye Bioscience Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Skye Bioscience's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Skye Bioscience's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book=Book Value per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.222/330.2130*330.2130
=0.222

Current CPI (Mar. 2026) = 330.2130.

Skye Bioscience Quarterly Data

Book Value per Share CPI Adj_Book
201606 -17.963 241.018 -24.611
201609 -26.500 241.428 -36.245
201612 -32.128 241.432 -43.942
201703 -24.697 243.801 -33.451
201706 -21.529 244.955 -29.022
201709 -22.024 246.819 -29.465
201712 -22.507 246.524 -30.148
201803 -8.804 249.554 -11.650
201806 -13.292 251.989 -17.418
201809 -16.298 252.439 -21.319
201812 -25.521 251.233 -33.544
201903 -46.007 254.202 -59.764
201906 -19.220 256.143 -24.778
201909 -27.785 256.759 -35.734
201912 0.673 256.974 0.865
202003 -2.102 258.115 -2.689
202006 -3.748 257.797 -4.801
202009 1.573 260.280 1.996
202012 0.322 260.474 0.408
202103 1.415 264.877 1.764
202106 1.190 271.696 1.446
202109 3.690 274.310 4.442
202112 2.726 278.802 3.229
202203 1.360 287.504 1.562
202206 -0.144 296.311 -0.160
202209 -1.672 296.808 -1.860
202212 -0.777 296.797 -0.864
202303 -1.149 301.836 -1.257
202306 -1.850 305.109 -2.002
202309 0.129 307.789 0.138
202312 -0.158 306.746 -0.170
202403 2.586 312.332 2.734
202406 2.410 314.175 2.533
202409 2.251 315.301 2.357
202412 2.101 315.605 2.198
202503 1.769 319.799 1.827
202506 1.222 322.561 1.251
202509 0.903 324.800 0.918
202512 0.512 324.054 0.522
202603 0.222 330.213 0.222

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Skye Bioscience Business Description

Other Exchanges SKYE:USA
Address 11250 El Camino Real, Suite 100, San Diego, CA, USA, 92130
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
19GF Score

Get the complete analysis for FRA:09R

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.55
Price